Dr Sagar Lonial presents the case of a 58-year-old man with relapsed/refractory multiple myeloma to the panel for discussion.
FDA ODAC Votes Belantamab Mafodotin Risks Outweigh Benefits in Myeloma
July 17th 2025The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, highlighting notable ocular toxicities and missed opportunities for dosing optimization.
Read More